Clinical Trial Update: Sorafenib Maintenance for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3 Negative Acute Leukemia [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial investigating sorafenib maintenance to prevent leukemia relapse after allogeneic hematopoietic stem cell transplantation in FLT3-negative acute …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Relapse of Acute Leukemia

Drugs mentioned

• Sorafenib (Sorafenib)

Snippet

Sponsor: Nanfang Hospital, Southern Medical University | Conditions: Acute Leukemia, Relapse | Phase 2, Phase 3 | Status: UNKNOWN